Can we use a stability study designed for our biosimilar since the reference drug information in the product monograph does not reflect our data? Are there exceptions to the standard requirement of reflecting the product monograph for biosimilars?
C
cscholes
@cscholes
The responses, guidance, and advisories provided by the Pharmaceutical Advertising Advisory Board (PAAB),
including but not limited to those available through the PAAB Forum, the PAAB website, and any PAAB
correspondences, are specifically intended to assist individuals navigating the PAAB preclearance system.
Repurposing or reproducing this content without written consent from the PAAB Commissioner is strictly
prohibited. This prohibition includes, but is not limited to, use in machine learning or AI models.
Posts
-
Use of Biosimilar-Specific Stability Data -
question on HCP targeted communication on LinkedInWe are reaching out in regards to guiding principles regarding communication with HCP via LinkedIn. Specifically, can we communicate about Brand Rx? In the PAAB FAQs we located information more in line with a DTC (question 458) but could not locate any information regarding targeted HCP.
We are looking to understand how you consider the qualification of HCP targeted only on LinkedIn in such a way that we can communicate about Rx brands (branded) with this audience the same way we can with reps, print or digital HCP media or via PTM